Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, and Phytonadione Injection.

Company Growth (employees)
Type
Public
HQ
Rancho Cucamonga, US
Founded
1996
Size (employees)
1,541 (est)+6%
Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has an office in Rancho Cucamonga
Rancho Cucamonga, US (HQ)
11570 6th St

Amphastar Pharmaceuticals Data and Metrics

Amphastar Pharmaceuticals Financial Metrics

Amphastar Pharmaceuticals's revenue was reported to be $56.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

56.7 m

Gross profit (Q1, 2017)

22.8 m

Gross profit margin (Q1, 2017), %

40%

Net income (Q1, 2017)

893 k

EBIT (Q1, 2017)

1.4 m

Market capitalization (22-Aug-2017)

741.4 m

Cash (31-Mar-2017)

76.8 m
Amphastar Pharmaceuticals's current market capitalization is $741.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

210.5 m251.5 m255.2 m

Revenue growth, %

20%1%

Cost of goods sold

159.2 m174.2 m151 m

Gross profit

51.3 m77.3 m104.2 m

Gross profit Margin, %

24%31%41%

Sales and marketing expense

5.6 m5.5 m5.5 m

R&D expense

28.4 m37.1 m41.2 m

General and administrative expense

34.8 m41.5 m41.8 m

Operating expense total

68.8 m84 m88.5 m

EBIT

(18 m)(6.9 m)15.7 m

EBIT margin, %

(9%)(3%)6%

Interest expense

609 k987 k1 m

Interest income

243 k315 k270 k

Pre tax profit

(18.1 m)(10.4 m)14.9 m

Income tax expense

(7.4 m)(7.6 m)4.4 m

Net Income

(10.7 m)(2.8 m)10.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

49 m59.7 m56.9 m53.9 m63.9 m59.4 m68 m64.2 m56.7 m

Cost of goods sold

34 m47.9 m43.6 m40.5 m46.3 m34.5 m36.3 m36.6 m33.8 m

Gross profit

15 m11.8 m13.3 m13.3 m17.6 m24.9 m31.7 m27.6 m22.8 m

Gross profit Margin, %

31%20%23%25%28%42%47%43%40%

R&D expense

6 m8.6 m6.6 m10.7 m11.1 m8.4 m10.5 m9.7 m11.3 m

General and administrative expense

8.6 m9.6 m12.5 m11.3 m9 m10.9 m9.5 m10.8 m11.3 m

Operating expense total

14.6 m18.1 m19 m22 m20.2 m19.3 m19.9 m20.5 m22.6 m

EBIT

(1.2 m)(7.8 m)(7.3 m)(10.3 m)(3.7 m)4.1 m10.3 m5.8 m1.4 m

EBIT margin, %

(2%)(13%)(13%)(19%)(6%)7%15%9%2%

Interest expense

476 k504 k341 k210 k232 k384 k305 k281 k191 k

Interest income

32 k94 k92 k65 k83 k74 k50 k63 k91 k

Pre tax profit

(1.9 m)(8 m)(6.2 m)(10.2 m)(4.3 m)3.8 m9.8 m6 m1.5 m

Income tax expense

(696 k)(2.6 m)(5.5 m)(3.6 m)(1.3 m)1.3 m2.9 m2.1 m611 k

Net Income

(1.2 m)(5.4 m)(665 k)(6.6 m)(3 m)2.5 m6.9 m3.9 m893 k
USDY, 2012Y, 2013FY, 2014FY, 2015FY, 2016

Cash

50.2 m53.6 m67.8 m66.1 m72.4 m

Accounts Receivable

22.9 m33.2 m26.8 m

Inventories

118.4 m

Current Assets

198 m175.9 m184.1 m

PP&E

138.3 m142.2 m152.9 m

Goodwill

42.6 m39.9 m50.3 m

Total Assets

389.4 m390.1 m427.7 m

Accounts Payable

10.2 m13.9 m16.2 m

Current Liabilities

62.6 m60 m60.6 m

Total Liabilities

98.5 m

Additional Paid-in Capital

220.7 m247.8 m283.1 m

Retained Earnings

63.1 m60.3 m70.9 m

Total Equity

295.5 m329.3 m

Financial Leverage

1.3 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

64.1 m72.9 m68.6 m74.5 m76.8 m

Accounts Receivable

18.6 m26.6 m21.7 m19.8 m25 m23.1 m23.1 m26.6 m25.9 m

Inventories

106 m88.1 m84.9 m80.2 m72.4 m82.2 m88.3 m90.7 m78.1 m

Current Assets

214.2 m215.2 m202.6 m203.9 m199.1 m173.4 m181.3 m190.2 m191.4 m

PP&E

134 m134.1 m138.3 m139.3 m141.2 m144.7 m148.6 m152 m157.4 m

Goodwill

39.3 m43.2 m41.3 m40.9 m40.5 m44 m43.3 m51.7 m46 m

Total Assets

397.3 m401.1 m396.5 m398.9 m395 m395 m408.6 m428.8 m435.6 m

Accounts Payable

17.8 m10 m18.9 m18.4 m12.3 m18.6 m18.8 m13.4 m19.3 m

Current Liabilities

56.3 m63.1 m72.1 m69.4 m70.7 m64.9 m65.7 m60.8 m72.9 m

Additional Paid-in Capital

217 m219.3 m223.3 m236.7 m240.7 m250.7 m258.8 m276.5 m285.4 m

Retained Earnings

71 m65.6 m62.4 m55.8 m52.8 m62.8 m69.7 m73.6 m72.6 m

Total Equity

285.3 m283.8 m296.6 m307.5 m328.5 m325.6 m

Financial Leverage

1.4 x1.4 x1.3 x1.3 x1.3 x1.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(10.7 m)(2.8 m)10.5 m

Depreciation and Amortization

12 m

Accounts Receivable

1.2 m6.4 m

Inventories

9.1 m(9.7 m)

Accounts Payable

7 m

Cash From Operating Activities

14.2 m(1.8 m)38.6 m

Purchases of PP&E

(18.7 m)

Cash From Investing Activities

(39.8 m)(39.5 m)

Long-term Borrowings

(8.2 m)(14.7 m)

Cash From Financing Activities

32.1 m7.1 m

Interest Paid

2.6 m

Income Taxes Paid

436 k3.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.2 m)(5.4 m)(665 k)(6.6 m)(3 m)2.5 m6.9 m3.9 m893 k

Accounts Receivable

18.6 m26.6 m21.7 m19.8 m25 m23.1 m23.1 m26.6 m25.9 m

Accounts Payable

17.8 m10 m18.9 m18.4 m12.3 m18.6 m18.8 m13.4 m19.3 m
USDY, 2017

Revenue/Employee

37.8 k

Financial Leverage

1.3 x

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Products

19

Facilities

5

Amphastar Pharmaceuticals Market Value History

Amphastar Pharmaceuticals Revenue Breakdown

Amphastar Pharmaceuticals Median Salaries

Source: 12 public H-1B filings from Amphastar Pharmaceuticals

Traffic Overview of Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Online and Social Media Presence

Amphastar Pharmaceuticals News and Updates

As need grows for painkiller overdose treatment, companies raise prices

Aimee Dunkle began helping to distribute the drug naloxone -- the life-saving antidote to prescription painkiller overdoses -- after her son died. Ben Dunkle, 20, was with three people when he overdosed in 2012, she said. She believes he would be alive today if they had naloxone. “They panicked,…

Amphastar Pharmaceuticals Company Life and Culture

You may also be interested in